Bright Minds Biosciences Inc. has created phenethlyamines acting as 5-HT2A receptor agonists and reported to be useful for the treatment of depression and anxiety disorders.
Atai Life Sciences AG has described 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment resistant depression, major depression, anxiety, eating, obsessive-compulsive and stress disorder.
Research at Reunion Neuroscience Inc. has led to the discovery of benzyltryptamine compounds acting as 5-HT2A receptor agonists. These compounds are reported to be useful for the treatment of depression, alcoholism, cocaine addiction, inflammation, cluster headache neurological and post-traumatic stress disorder.
Diamond Therapeutics Inc. has identified deuterated lisuride analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of neurological disorders.
Mindset Pharma Inc. has patented indole derivatives acting as 5-HT2A receptor agonists and reported to be useful for the treatment of neurological disorders and psychosis.
Columbia University has presented non-hallucinogenic ariadne analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, among other disorders.
